The landscape of drug discovery in atherosclerosis and dyslipidaemia: a survey from patenting activity

Bibliography

• Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006;5:295-309
   PubMed Web of Science ®Google Scholar
• Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque. Part I. Evolving concepts. J Am Coll Cardiol 2005;46:937-54
   PubMed Web of Science ®Google Scholar
• Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004;25:1197-207
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C. Statins: are any questions unanswered? Curr Opin Lipidol 2006;17:418-25
   PubMed Web of Science ®Google Scholar
• Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006;111:893-908
   PubMed Web of Science ®Google Scholar
• Meagher E, Rader DJ. Antioxidant therapy and atherosclerosis: animal and human studies. Trends Cardiovasc Med 2001;11:162-5
   PubMedGoogle Scholar
• Kaliora AC, Dedoussis GV, Schmidt H. Dietary antioxidants in preventing atherogenesis. Atherosclerosis 2006;187:1-17
   PubMed Web of Science ®Google Scholar
• Moubayed SP, Heinonen TM, Tardif JC. Anti-inflammatory drugs and atherosclerosis. Curr Opin Lipidol 2007;18:638-44
   PubMed Web of Science ®Google Scholar
• Chapman MJ. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention. Pharmacol Ther 2007;113:184-96
   PubMedGoogle Scholar
• Ferri N, Paoletti R, Corsini A. Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation. Curr Opin Lipidol 2006;17:495-501
   PubMed Web of Science ®Google Scholar
• Duivenvoorden R, Nederveen AJ De GE, Kastelein JJ. Atherosclerosis imaging as a benchmark in the development of novel cardiovasular drugs. Curr Opin Lipidol 2007;18:613-21
   PubMed Web of Science ®Google Scholar
• Esp@cenet. European Patent Office. Available from: http://ep.espacenet.com [Last accessed January 2008]
   Google Scholar
• Viles-Gonzalez JF, Fuster V, Corti R, et al. Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. Curr Opin Cardiol 2003;18:286-94.
   PubMed Web of Science ®Google Scholar
• Rader DJ. Illuminating HDL: is it still a viable therapeutic target? N Engl J Med 2007;357:2180-3
   PubMed Web of Science ®Google Scholar
• Alegret M, Silvestre JS, Castaner J. JTT-705: treatment of lipoprotein disorders cholesteryl ester transfer protein inhibitor. Drugs Future 2004;29:787-92
   Google Scholar
• Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370:1907-14
   PubMed Web of Science ®Google Scholar
• Carlson LA. Nicotinic acid and other therapies for raising high-density lipoprotein. Curr Opin Cardiol 2006;21:336-44
   PubMed Web of Science ®Google Scholar
• Levy E, Spahis S, Sinnett D, et al. Intestinal cholesterol transport proteins: an update and beyond. Curr Opin Lipidol 2007;18:310-8
   PubMed Web of Science ®Google Scholar
• Gotto AM Jr, Farmer JA. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol. Nat Clin Pract Cardiovasc Med 2006;3:664-72
   PubMedGoogle Scholar
• Suckling K. The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibe. Expert Opin Pharmacother 2007;9:1067-70
   Google Scholar
• Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007;115:518-33
   PubMed Web of Science ®Google Scholar
• Geyeregger R, Zeyda M, Stulnig TM. Liver X receptors in cardiovascular and metabolic disease. Cell Mol Life Sci 2006;63:524-39
   PubMed Web of Science ®Google Scholar
• Berkenstam A, Kristensen J, Mellstrom K, et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 2007;105:663-7
   PubMed Web of Science ®Google Scholar
• Linden D, William-Olsson L, Ahnmark A, et al. Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation. FASEB J 2006;20:434-43
   PubMedGoogle Scholar
• Ntambi JM, Miyazaki M. Regulation of stearoyl-CoA desaturases and role in metabolism. Prog Lipid Res 2004;43:91-104
   PubMed Web of Science ®Google Scholar
• Glaros EN, Kim WS, Wu BJ, et al. Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem Pharmacol 2007;73:1340-6
   PubMedGoogle Scholar
• Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol 2007;18:304-9
   PubMed Web of Science ®Google Scholar
• Sebokova E, Christ AD, Boehringer M, et al. Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes. Curr Top Med Chem 2007;7:547-55
   PubMed Web of Science ®Google Scholar
• Gualillo O, Gonzalez-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007;17:275-83
   PubMed Web of Science ®Google Scholar
• Wang M. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome. Curr Opin Investig Drugs 2006;7:319-23
   PubMedGoogle Scholar
• Suckling K. Drug discovery in the metabolic syndrome: context and some recent developments. Expert Opin Ther Targets 2007;11:801-8
   PubMed Web of Science ®Google Scholar
• Sasaoka T, Wada T, Tsuneki H. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity. Pharmacol Ther 2006;112:799-809
   PubMed Web of Science ®Google Scholar
• Sorbera LA, Castaner J. AGI-1067. Treatment of atherosclerosis, VCAM-1 and MCP-1 expression inhibitor, antioxidant. Drugs Future 2003;28:421-4
   Google Scholar
• Wells TN, Power CA, Shaw JP, Proudfoot AE. Chemokine blockers: therapeutics in the making? Trends Pharmacol Sci 2006;27:41-7
   PubMed Web of Science ®Google Scholar
• Feria M, Gonzalez F. The CCR2 receptor as a therapeutic target. Expert Opin Ther Patents 2006;16:49-57
   Web of Science ®Google Scholar
• Nicholls SJ, Zheng LM, Hazen SL. Formation of dysfunctional high-density lipoprotein by myeloperoxidase [Review]. Trends Cardiovasc Med 2005;15:212-9
   PubMedGoogle Scholar
• McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006;47:726-33
   PubMed Web of Science ®Google Scholar
• Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 2007;50:17-24
   PubMed Web of Science ®Google Scholar
• Adhikari N, Charles N, Lehmann U, Hall JL. Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury. Curr Atheroscler Rep 2006;8:252-60
   PubMedGoogle Scholar
• Cuccurullo C, Iezzi A, Fazia ML, et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006;26:2716-23
   PubMed Web of Science ®Google Scholar
• Takaya T, Hirata K, Yamashita T, et al. A specific role for eNOS-derived reactive oxygen species in atherosclerosis progression. Arterioscler Thromb Vasc Biol 2007;27:1632-7
   PubMedGoogle Scholar
• Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med 2005;2:529-35
   PubMedGoogle Scholar
• Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25:923-31
   PubMed Web of Science ®Google Scholar
• Zhao L, Funk CD. Lipoxygenase pathways in atherogenesis [Review]. Trends Cardiovasc Med 2004;14:191-5
   PubMed Web of Science ®Google Scholar
• Back M, Sultan A, Ovchinnikova O, Hansson GK. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 2007;100:946-9
   PubMed Web of Science ®Google Scholar
• Qiu H, Gabrielsen A, Agardh HE, et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 2006;103:8161-6
   PubMed Web of Science ®Google Scholar
• Anantharamaiah GM, Navab M, Reddy ST, et al. Synthetic peptides: managing lipid disorders. Curr Opin Lipidol 2006;17:233-7
   PubMedGoogle Scholar
• Suckling KE. The return of two old targets? Expert Opin Ther Targets 2006;10:785-8
   PubMed Web of Science ®Google Scholar
• Ikenoya M, Yoshinaka Y, Kobayashi H, et al. A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis 2007;191:290-7
   PubMedGoogle Scholar
• Shiomi M, Yamada S, Amano Y, et al. Stabilization of coronary atherosclerosis by a squalene synthase inhibitor. Atherosclerosis 2006;7:339
   Google Scholar
• Umehara H, Bloom ET, Okazaki T, et al. Fractalkine in vascular biology: from basic research to clinical disease [Review]. Arterioscler Thromb Vasc Biol 2004;24:34-40
   PubMed Web of Science ®Google Scholar
• Lilly SM, Rader DJ. New targets and emerging therapies for reducing LDL cholesterol. Curr Opin Lipidol 2007;18:650-5
   PubMed Web of Science ®Google Scholar